Callio Therapeutics
Seattle
About Callio Therapeutics
Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $187.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Mar 2025)
- Website: calliotx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/callio-therapeutics-78717 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.